Physician profile
Ann C Stuart
NPI 1699873554
$7,810.66
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,692 · 2020: $1,710 · 2021: $1,683 · 2022: $1,951 · 2023: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,013.83 | 2019-2023 | Wegovy |
| Lilly USA, LLC | $655.58 | 2019-2023 | Mounjaro |
| Abbvie INC. | $570.86 | 2019-2023 | Vraylar, Qulipta |
| Pfizer INC. | $513.24 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $477.73 | 2019-2023 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals Lp | $464.22 | 2019-2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $402.69 | 2019-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $402.61 | 2019-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Amarin Pharma, INC. | $398.69 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $251.03 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $244.79 | 2019-2023 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $205.13 | 2022-2023 | |
| Antares Pharma, INC. | $186.45 | 2019-2023 | Tlando, Nocdurna, Xyosted |
| Astellas Pharma US INC | $171.26 | 2019-2023 | Veozah |
| Merck Sharp & Dohme LLC | $170.11 | 2019-2023 | Verquvo, Belsomra |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $169.71 | 2019-2023 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $167.98 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $167.03 | 2019-2023 | |
| Arbor Pharmaceuticals, INC. | $158.63 | 2019-2022 | |
| Allergan, INC. | $156.50 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $146.76 | 2022 | |
| Eisai INC. | $122.98 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $104.11 | 2019-2022 | |
| Mylan Specialty L.P. | $81.52 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $73.21 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $47.61 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $46.42 | 2021 | |
| Clarus Therapeutics INC. | $45.55 | 2021 | |
| Esperion Therapeutics, INC. | $38.17 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $36.21 | 2021-2022 | |
| Genentech USA, INC. | $24.60 | 2019 | |
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| Axsome Therapeutics, INC. | $17.82 | 2022 | |
| Halozyme INC | $16.67 | 2023 | |
| Azurity Pharmaceuticals, INC. | $16.60 | 2023 | Edarbyclor |
| Alexion Pharmaceuticals, INC. | $14.20 | 2020 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Stuart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.